Navigation Links
Children's Oncology Group and Apeiron to Jointly Conduct Phase II Study in Neuroblastoma With hu14.18-IL2 (APN301)
Date:9/29/2011

hilanthropic resources to go directly to COG's worldwide team of researchers committed to turning new discoveries into better treatments.

About Apeiron (as of September 2011):

Apeiron is a privately financed biotech based in Vienna, Austria. Apeiron focuses on biological and immunological treatments against cancer and related conditions. Including the recently closed licence agreement for the phase III project Mab ch14.18/CHO (APN311), Apeiron's project portfolio consists of five projects under clinical evaluation, and four preclinical projects. Clinical projects include the immunocytokine hu14.18-IL2 (APN301) that is about to enter a phase II (for certain neuroblastoma patients) shortly and is also being clinically tested against melanoma. Also in clinical stage is a liposomal formulation of recombinant human Superoxide Dismutase (APN201) to prevent or treat skin damage due to radiation treatment in cancer. A further clinical project, recombinant human Angiotensin Converting Enzyme 2 (APN01), was licensed to GlaxoSmithKline early 2010. It is expected to commence a phase II study for the treatment of Acute Respiratory Distress Syndrome in the near future and has considerable potential in other disease areas. Apeiron is operational since 2006 and employs approx. 25 people.

About APN301:

APN301 (hu14.18-IL2) is a recombinant fusion protein that consists of the humanized 14.18 monoclonal antibody, which recognizes the GD2 disialoganglioside, strongly expressed on virtually all cases of human neuroblastoma, as well as on several other human cancer types (including melanoma, small cell lung carcinoma, osteosarcoma, and soft-tissue sarcoma), linked genetically to human recombinant interleukin-2 (IL2) lymphokine. IL2 has been tested extensively in clinical cancer trials and is approved as an immune activator with documented anti-tumor effects in certain cancers (melanoma and renal cell cancer).

In patients, hu14.18-IL2 localizes to GD2-po
'/>"/>

SOURCE APEIRON Biologics AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. XECAN and Trimble Partner to Deliver ThingMagic Powered RFID Oncology Solution
2. Champions Oncology Clarifies Misstatements in News Article
3. Medicare HIT Incentive Update for the Oncology Practice - Free Educational Webinar
4. Champions Oncology Reports Full Year 2011 Financial Results
5. McKesson Specialty Care Solutions
6. US Oncology Honors Five Exceptional Oncology Nurses for Outstanding Work
7. Genentech and Novartis Remain Image Leaders in Oncology and Hematology
8. Oncology National Commercial (ONC) Study Outlines 10 Trends Shaping the Market for Oncology Pharmaceutical and Biotech Products
9. Reportlinker Adds Innovations in Protein Kinase Therapies - Significant Proportion of Protein Kinase Pipeline Contains Small Molecule Drugs That Target Oncology
10. Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting
11. Beardsworth Continues to Strengthen Oncology Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 21, 2015  The EveryLife Foundation for Rare ... and Amy Klobuchar (D-MN) today for ... & Treatments, or OPEN ACT. Supported ... organizations, this bipartisan legislation promises to rapidly bring ... rare disease patients by incentivizing drug makers to ...
(Date:5/21/2015)... 2015 Patent Offering, The patent’s technology ... or therapeutic imaging within a body lumen (open space). ... having a low cost, single-use disposable illumination and camera ... October 18, 2013 and the patent approval was received ... physician to customize the lighting and magnification of the ...
(Date:5/21/2015)... Research and Markets ( http://www.researchandmarkets.com/research/84975r/2015_global ... "2015 Global Survey on Flow Cytometry Adoption Trends" ... primary goal of this research is to analyze ... Key information the survey seeks to collect include ... predominantly used applications for flow cytometers, respondents, most ...
(Date:5/21/2015)... 21, 2015 Tunnell Consulting, ... firm as senior statistician and Principal, a position to ... in the management and analysis of complex and large ... industries. , “We’re delighted to have Julia join the ... analytics,” said Dr. Philippe Cini, Group Vice President and ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 3Global Survey on Flow Cytometry Adoption Trends 2015 2Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2
... VIEW, Calif., Jan. 30 /PRNewswire/ -- ... genome sequencing company, today announced that it will release ... the 10th annual Advances in Genome Biology and Technology ... from Feb. 4-7.Dr. Clifford Reid, chairman, president and CEO ...
... announced today that it intends to commence a cash tender ... 86.50 per share. Roche, which currently owns 55.8% of the ... approximately two weeks. The offer replaces the public proposal made ... the publicly-held shares of Genentech at a price of US$ ...
... Basic Sciences award in this inaugural edition of the ... by physicists Peter Zoller (Austria, 1952) and Ignacio Cirac ... science", in the words of the jury chaired by ... Cirac,s research is opening up vital new avenues for ...
Cached Biology Technology:Roche Intends to Commence Tender Offer to Acquire All Shares of Genentech for US$ 86.50 Per Share in Cash 2Roche Intends to Commence Tender Offer to Acquire All Shares of Genentech for US$ 86.50 Per Share in Cash 3Roche Intends to Commence Tender Offer to Acquire All Shares of Genentech for US$ 86.50 Per Share in Cash 4Roche Intends to Commence Tender Offer to Acquire All Shares of Genentech for US$ 86.50 Per Share in Cash 5Peter Zoller and Ignacio Cirac, awarded by the BBVA Foundation 2
(Date:4/20/2015)... 2015 The announcement comes as ... Records Management (GRM), Ireland,s foremost records ... Having built up an impressive track record of clients within ... within the records management sector in Dubai ... GCC staffbase and employ a further eight staff members at ...
(Date:4/14/2015)...  HYPR Corp. today announced it has joined ... tm , an industry consortium transforming online authentication ... technology and collaborate to deliver open specifications for ... and private, and easier to use. ... sensitive user information and eliminates the dependency on ...
(Date:4/13/2015)... , April 13, 2015 ... Research, "Global Biometrics Market Forecast & Opportunities, 2020", the ... CAGR of around 14% till 2020. The biometrics ... large scale implementation and review of biometric management ... of new products with greater efficiency, are resulting ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... Tactile Sensors at Your Fingertips, Literally, ... Systems, Inc.,(PPS) today announces their innovative new ... immediate sale worldwide. FingerTPS,sensors are soft, flexible ... accurate,repeatable tactile force data to a PC ...
... the mastermind behind a project that has led to an ... on an endangered species of ape. Ursula Goodenough, ... driving force behind I,m Lucy, A Day in the ... Goodenough,s daughter, and featuring the photographs of St. Louisan Marian ...
... a staggering number of cells perform a feat that still ... replicas of each other. The process is called mitosis, and ... of cancer. Little is known about the ... Chase Cancer Center and Technion-Israel Institute of Technology in Haifa, ...
Cached Biology News:Wearable Sensors Conceived at Harvard Robotics Lab Measure Hand Forces 2Book's plea: Save the bonobos 2Book's plea: Save the bonobos 3Book's plea: Save the bonobos 4Death, division or cancer? Newly discovered checkpoint process holds the line in cell division 2Death, division or cancer? Newly discovered checkpoint process holds the line in cell division 3
NATIVE PORCINE COLIPASE...
Polyclonal Antibody to CRTR-1...
Recognizes NSCL1. The molecular weight of the protein is 14,616 Daltons....
Mouse monoclonal [3G131] to Desmoglein 1 ( Abpromise for all tested applications). entrezGeneID: 1828 SwissProtID: Q02413...
Biology Products: